A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Imalumab (Primary) ; Fluorouracil; Panitumumab
- Indications Colon cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Baxalta; Baxter Corporation
- 02 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 02 Mar 2017 This study has been completed in Spain as Eudra(end date- 2017-02-18)
- 15 Aug 2016 Status changed from recruiting to active, no longer recruiting.